Infliximab for ulcerative colitis following liver transplantation.
Primary sclerosing cholangitis is a chronic cholestatic disease with a progressive course, often culminating in hepatic transplantation. When associated with primary sclerosing cholangitis, ulcerative colitis commonly follows a mild course before, but a more progressive course following liver transplantation, with a significant proportion of patients becoming steroid dependent and/or requiring colectomy. We report the first case demonstrating the efficacy and safety of infliximab therapy for ulcerative colitis following hepatic transplantation.
Lal
Simon
S
Department of Gastroenterology, University Hospitals, Aintree, Liverpool, UK.
Steinhart
A Hillary
AH
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015209:Cholangitis, Sclerosing / Q000601:surgery; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D003113:Colonoscopy; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D016031:Liver Transplantation / Q000009:adverse effects*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab